Anti-Fibronectin (bovine, human)

CAT. NO. CSI 005-32

OVERVIEW

Product Name	Anti-Fibronectin (bovine, human)	**Conjugation**	Unconjugated
Description	Mouse monoclonal antibody	**Host**	Mouse
Isotype	IgG1/k	**Clone**	A32
Tested Applications	ELISA, WB, IHC, IP		

SPECIFICITY

Specificity	CSI 005-32 is highly specific for fibronectin. There is no evidence for cross-reactivity with other connective tissue proteins (vitronectin, elastin, collagen, laminin). The antibody inhibits cell adhesion to fibronectin mediated by the heparin-binding domain. Epitope is located in the 40kD Hep II heparin-binding domain.		
Immunogen	Bovine corneal endothelial cells	**Gene ID**	280794, 2335
Target	Fibronectin is an adhesive glycoprotein with a molecular mass of 440 kDa. It is believed to be important for the formation of a provisional matrix that promotes cell adhesion and migration during wound healing. Its age-dependent increase in plasma and tissues may be accompanied in pathological states, especially in tumor growth, by its proteolytic breakdown by a number of neutral proteases. It has also shown that several of its proteolytic breakdown products exhibit unexpected and mostly harmful biological activities. (1)		
Species Reactivity POSITIVE	Bovine, Human	**Species Reactivity NEGATIVE**	Not determined

PROPERTIES

Form	Liquid	**Unit Size**	0,4 mL and 1 mL
Concentration	1 mg/mL ±15%, See CoA for lot details		
Purification	Protein A or Protein G purified	**Purification Notes**	BSA free
Storage buffer	0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide		
Storage condition	2-8°C without exposure to light		
Safety	Wear protective clothing		

TESTED APPLICATIONS

ELISA	CSI 005-32 can be used in ELISA. It can be used to probe fibronectin conformation and to quantitate plasma fibronectin in a sandwich ELISA with antibody CSI 005-35. (1, 2, 3, 4)
WB	In Western blotting dilution guideline of 1/100 has proved successful. (1)
IHC	CSI 005-32 can be used in immunostaining of frozen PLP-fixed sections of bovine and human tissues.
IP	CSI 005-32 can be used in immunoprecipitation.

SCIENTIFIC REFERENCES

1. Underwood PA, Dalton BA, Steele JG, Bennett FA, Strike P (1992) Anti-fibronectin antibodies that modify heparin binding and cell adhesion: evidence for a new cell binding site in the heparin binding region. J Cell Sci 102:833-845.

2. Underwood PA, Steele JG, Dalton BA (1993) Effects of polystyrene surface chemistry on biological activity of solid phase fibronectin and vitronectin, analysed with monoclonal antibodies. J Cell Sci 104:793-803.

3. Di Girolamo N, Underwood PA, McCluskey PJ, Wakefield D (1993) Functional activity of plasma fibronectin in patients with Diabetes mellitis. Diabetes 42:1606-1613.

CONDITIONS
Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.

4. Dalton BA, McFarland CD, Underwood PA, Steele JG (1995) Role of heparin binding domain of fibronectin in attachment and spreading of human bone derived cells. J Cell Sci 108:2083-2092.

CONDITIONS
Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.